# Mesalamine to Reduce T Cell Activation in HIV Infection

> **NCT01090102** · PHASE4 · COMPLETED · sponsor: **University of California, San Francisco** · enrollment: 33 (actual)

## Conditions studied

- HIV Infections
- Sexually Transmitted Diseases
- Immune System Diseases
- Lentivirus Infections
- Acquired Immunodeficiency Syndrome

## Interventions

- **DRUG:** Mesalamine (5-aminosalicylic acid, Apriso)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01090102
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2014-08-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01090102

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01090102, "Mesalamine to Reduce T Cell Activation in HIV Infection". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01090102. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*